{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:12:07Z","timestamp":1791216727189,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05613-5","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T14:02:57Z","timestamp":1715781777000},"page":"2357-2370","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy and safety of intravenous immunoglobulin therapy in systemic sclerosis: a systematic review"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1154-8832","authenticated-orcid":false,"given":"Sandra","family":"Garrote-Corral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Botello Corzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Loarce-Martos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"de la Puente Bujidos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"5613_CR1","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton CP, Khanna D (2017) Systemic sclerosis. Lancet 390:1685\u20131699. https:\/\/doi.org\/10.1016\/S0140-6736(17)30933-9","journal-title":"Lancet"},{"key":"5613_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1007\/s12026-014-8615-z","volume":"61","author":"L Cantarini","year":"2015","unstructured":"Cantarini L, Rigante D, Vitale A, Napodano S, Sakkas LI, Bogdanos DP et al (2015) Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future. Immunol Res 61:326\u2013337. https:\/\/doi.org\/10.1007\/s12026-014-8615-z","journal-title":"Immunol Res"},{"key":"5613_CR3","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore Y, Simms R, Distler O, Trojanowska M, Pope J, Denton CP et al (2015) Systemic sclerosis. Nat Rev Dis Primers 1:15002. https:\/\/doi.org\/10.1038\/nrdp.2015.2","journal-title":"Nat Rev Dis Primers"},{"key":"5613_CR4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, Becker M, Kulak A, Allanore Y et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909","journal-title":"Ann Rheum Dis"},{"key":"5613_CR5","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrrheum.2011.61","volume":"7","author":"J Bayry","year":"2011","unstructured":"Bayry J, Negi VS, Kaveri SV (2011) Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 7:349\u2013359. https:\/\/doi.org\/10.1038\/nrrheum.2011.61","journal-title":"Nat Rev Rheumatol"},{"key":"5613_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/nri3401","volume":"13","author":"I Schwab","year":"2013","unstructured":"Schwab I, Nimmerjahn F (2013) Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 13:176\u2013189. https:\/\/doi.org\/10.1038\/nri3401","journal-title":"Nat Rev Immunol"},{"key":"5613_CR7","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1365-2249.2010.04295.x","volume":"163","author":"M Kajii","year":"2011","unstructured":"Kajii M, Suzuki C, Kashihara J, Kobayashi F, Kubo Y, Miyamoto H et al (2011) Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma. Clin Exp Immunol 163:235\u2013241. https:\/\/doi.org\/10.1111\/j.1365-2249.2010.04295.x","journal-title":"Clin Exp Immunol"},{"key":"5613_CR8","doi-asserted-by":"publisher","first-page":"15102","DOI":"10.1038\/s41598-023-42464-9","volume":"13","author":"S Speca","year":"2023","unstructured":"Speca S, Farhat MM, Jendoubi M, Guerrier T, Sanges S, Staumont-Salle D et al (2023) Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis. Sci Rep 13:15102. https:\/\/doi.org\/10.1038\/s41598-023-42464-9","journal-title":"Sci Rep"},{"key":"5613_CR9","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1002\/art.10363","volume":"46","author":"M Blank","year":"2002","unstructured":"Blank M, Levy Y, Amital H, Shoenfeld Y, Pines M, Genina O (2002) The role of intravenous immunoglobulin therapy in mediating skin fibrosis in tight skin mice. Arthritis Rheum 46:1689\u20131690. https:\/\/doi.org\/10.1002\/art.10363","journal-title":"Arthritis Rheum"},{"key":"5613_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"5613_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230510","author":"AT Masi","year":"1980","unstructured":"Masi AT et al (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). subcommittee for scleroderma criteria of the american rheumatism association diagnostic and therapeutic criteria committee. Arthritis Rheum. https:\/\/doi.org\/10.1002\/art.1780230510","journal-title":"Arthritis Rheum"},{"key":"5613_CR12","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F van den Hoogen","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747\u20131755. https:\/\/doi.org\/10.1136\/annrheumdis-2013-204424","journal-title":"Ann Rheum Dis"},{"key":"5613_CR13","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"5613_CR14","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hernan MA, Reeves BC, Savovic J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"5613_CR15","first-page":"151","volume":"31","author":"K Takehara","year":"2013","unstructured":"Takehara K, Ihn H, Sato S (2013) A randomized, double-blind, placebo-controlled trial: intravenous immunoglobulin treatment in patients with diffuse cutaneous systemic sclerosis. Clin Exp Rheumatol 31:151\u2013156","journal-title":"Clin Exp Rheumatol"},{"key":"5613_CR16","doi-asserted-by":"publisher","first-page":"102981","DOI":"10.1016\/j.autrev.2021.102981","volume":"20","author":"E Agostini","year":"2021","unstructured":"Agostini E, De Luca G, Bruni C, Bartoli F, Tofani L, Campochiaro C et al (2021) Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experience. Autoimmun Rev 20:102981. https:\/\/doi.org\/10.1016\/j.autrev.2021.102981","journal-title":"Autoimmun Rev"},{"key":"5613_CR17","doi-asserted-by":"publisher","first-page":"102431","DOI":"10.1016\/j.autrev.2019.102431","volume":"19","author":"B Chaigne","year":"2020","unstructured":"Chaigne B, Rodeia S, Benmostefa N, B\u00e9r\u00e9zn\u00e9 A, Authier J, Cohen P et al (2020) Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients. Autoimmun Rev 19:102431. https:\/\/doi.org\/10.1016\/j.autrev.2019.102431","journal-title":"Autoimmun Rev"},{"key":"5613_CR18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3899\/jrheum.140833","volume":"42","author":"CL Poelman","year":"2015","unstructured":"Poelman CL, Hummers LK, Wigley FM, Anderson C, Boin F, Shah AA (2015) Intravenous immunoglobulin may be an effective therapy for refractory, active diffuse cutaneous systemic sclerosis. J Rheumatol 42:236\u2013242. https:\/\/doi.org\/10.3899\/jrheum.140833","journal-title":"J Rheumatol"},{"key":"5613_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/art.20195","volume":"50","author":"Y Levy","year":"2004","unstructured":"Levy Y, Amital H, Langevitz P, Nacci F, Righi A, Conforti L et al (2004) Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: An open-label study. Arthritis Rheum 50:1005\u20131007. https:\/\/doi.org\/10.1002\/art.20195","journal-title":"Arthritis Rheum"},{"key":"5613_CR20","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1136\/ard.2006.060111","volume":"66","author":"F Nacci","year":"2007","unstructured":"Nacci F, Righi A, Conforti ML, Miniati I, Fiori G, Martinovic D et al (2007) Intravenous immunoglobulins improve the function and ameliorate joint involvement in systemic sclerosis: A pilot study. Ann Rheum Dis 66:977\u2013979. https:\/\/doi.org\/10.1136\/ard.2006.060111","journal-title":"Ann Rheum Dis"},{"key":"5613_CR21","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1111\/j.1365-2133.2007.07777.x","volume":"156","author":"H Ihn","year":"2007","unstructured":"Ihn H, Mimura Y, Yazawa N, Jinnin M, Asano Y, Yamane K et al (2007) High-dose intravenous immunoglobulin infusion as treatment for diffuse scleroderma. Br J Dermatol 156:1058\u20131060. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.07777.x","journal-title":"Br J Dermatol"},{"key":"5613_CR22","first-page":"S168","volume":"33","author":"KE Clark","year":"2015","unstructured":"Clark KE, Etomi O, Denton CP, Ong VH, Murray CD (2015) Intravenous immunogobulin therapy for severe gastrointestinal involvement in systemic sclerosis. Clin Exp Rheumatol 33:S168\u2013S170","journal-title":"Clin Exp Rheumatol"},{"key":"5613_CR23","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/rheumatology\/kev318","volume":"55","author":"J Raja","year":"2016","unstructured":"Raja J, Nihtyanova SI, Murray CD, Denton CP, Ong VH (2016) Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosis. Rheumatology (Oxford) 55:115\u2013119. https:\/\/doi.org\/10.1093\/rheumatology\/kev318","journal-title":"Rheumatology (Oxford)"},{"key":"5613_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.02.008","author":"S Sanges","year":"2017","unstructured":"Sanges S, Riviere S, Mekinian A, Martin T, Le Quellec A, Chatelus E et al (2017) Intravenous immunoglobulins in systemic sclerosis: data from a French nationwide cohort of 46 patients and review of the literature. Autoimmun Rev. https:\/\/doi.org\/10.1016\/j.autrev.2017.02.008","journal-title":"Autoimmun Rev"},{"key":"5613_CR25","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s12026-018-9047-y","volume":"66","author":"M Lidar","year":"2018","unstructured":"Lidar M, Masarwa S, Rotman P, Carmi O, Rabinowicz N, Levy Y (2018) Intravenous immunoglobulins for rheumatic disorders and thromboembolic events-a case series and review of the literature. Immunol Res 66:668\u2013674. https:\/\/doi.org\/10.1007\/s12026-018-9047-y","journal-title":"Immunol Res"},{"key":"5613_CR26","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00508-020-01669-y","volume":"133","author":"D Perkovic","year":"2021","unstructured":"Perkovic D, Petric M, Bozic I, Boric K, Marasovic Krstulovic D, Radic M et al (2021) Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis\u202f: Single centre experience. Wien Klin Wochenschr 133:1070\u20131075. https:\/\/doi.org\/10.1007\/s00508-020-01669-y","journal-title":"Wien Klin Wochenschr"},{"key":"5613_CR27","doi-asserted-by":"publisher","first-page":"103441","DOI":"10.1016\/j.autrev.2023.103441","volume":"22","author":"J Tandaipan","year":"2023","unstructured":"Tandaipan J, Guillen-Del-Castillo A, Simeon-Aznar CP, Carreira PE, De la Puente C, Narvaez J et al (2023) Immunoglobulins in systemic sclerosis management A large multicenter experience. Autoimmun Rev 22:103441. https:\/\/doi.org\/10.1016\/j.autrev.2023.103441","journal-title":"Autoimmun Rev"},{"key":"5613_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11226665","author":"FA Mendoza","year":"2022","unstructured":"Mendoza FA, DiMarino A, Cohen S, Adkins C, Abdelbaki S, Rattan S et al (2022) Treatment of Severe Swallowing Dysfunction in Systemic Sclerosis with IVIG: Role of Antimuscarinic Antibodies. J Clin Med. https:\/\/doi.org\/10.3390\/jcm11226665","journal-title":"J Clin Med"},{"key":"5613_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17202","author":"KM Matsuda","year":"2023","unstructured":"Matsuda KM, Sugimoto E, Ako Y, Kitamura M, Miyahara M, Kotani H et al (2023) Reliability, validity, and sensitivity of Japanese version of the UCLA Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument: application to efficacy assessment of intravenous immunoglobulin administration. J Dermotol. https:\/\/doi.org\/10.1111\/1346-8138.17202","journal-title":"J Dermotol"},{"key":"5613_CR30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jdermsci.2012.09.010","volume":"69","author":"H Kudo","year":"2013","unstructured":"Kudo H, Jinnin M, Yamane K, Makino T, Kajihara I, Makino K et al (2013) Intravenous immunoglobulin treatment recovers the down-regulated levels of Th1 cytokines in the sera and skin of scleroderma patients. J Dermatol Sci 69:77\u201380. https:\/\/doi.org\/10.1016\/j.jdermsci.2012.09.010","journal-title":"J Dermatol Sci"},{"key":"5613_CR31","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1136\/annrheumdis-2023-eular.2525","volume":"82","author":"CP Denton","year":"2023","unstructured":"Denton CP, Kowal-Bielecka O, Proudman S, Olesiiska M, Worm M, Del Papa N et al (2023) Safety and pharmacokinetics of igpro20 (subcutaneous immunoglobulin) and igpro10 (intravenous immunoglobulin) in adults with systemic sclerosis (SSC)-results from a phase 2 trial. Ann Rheum Dis 82:985. https:\/\/doi.org\/10.1136\/annrheumdis-2023-eular.2525","journal-title":"Ann Rheum Dis"},{"key":"5613_CR32","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1111\/1756-185X.13716","volume":"22","author":"L Zhong","year":"2019","unstructured":"Zhong L, Pope M, Shen Y, Hernandez JJ, Wu L (2019) Prevalence and incidence of systemic sclerosis: A systematic review and meta-analysis. Int J Rheum Dis 22:2096\u20132107. https:\/\/doi.org\/10.1111\/1756-185X.13716","journal-title":"Int J Rheum Dis"},{"key":"5613_CR33","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1093\/rheumatology\/keh600","volume":"44","author":"Y Asano","year":"2005","unstructured":"Asano Y, Ihn H, Asashima N, Yazawa N, Mimura Y, Jinnin M et al (2005) A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion. Rheumatology 44:824\u2013826. https:\/\/doi.org\/10.1093\/rheumatology\/keh600","journal-title":"Rheumatology"},{"key":"5613_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.102997","author":"RP Goswami","year":"2021","unstructured":"Goswami RP, Haldar SN, Chatterjee M, Vij P, van der Kooi AJ, Lim J et al (2021) Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis. Autoimmun Rev. https:\/\/doi.org\/10.1016\/j.autrev.2021.102997","journal-title":"Autoimmun Rev"},{"key":"5613_CR35","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","volume":"387","author":"R Aggarwal","year":"2022","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csorgo Z, Dimachkie MM, Griger Z et al (2022) Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med 387:1264\u20131278. https:\/\/doi.org\/10.1056\/NEJMoa2117912","journal-title":"N Engl J Med"},{"key":"5613_CR36","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5114\/ada.2018.72662","volume":"35","author":"E Wielosz","year":"2018","unstructured":"Wielosz E, Majdan M, Dryglewska M, Targonska-Stepniak B (2018) Overlap syndromes in systemic sclerosis. Postepy Dermatol Alergol 35:246\u2013250. https:\/\/doi.org\/10.5114\/ada.2018.72662","journal-title":"Postepy Dermatol Alergol"},{"key":"5613_CR37","doi-asserted-by":"publisher","first-page":"247","DOI":"10.5301\/jsrd.5000214","volume":"1","author":"AB Shreiner","year":"2016","unstructured":"Shreiner AB, Murray C, Denton C, Khanna D (2016) Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord 1:247\u2013256. https:\/\/doi.org\/10.5301\/jsrd.5000214","journal-title":"J Scleroderma Relat Disord"},{"key":"5613_CR38","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.semarthrit.2016.02.005","volume":"46","author":"C Frantz","year":"2016","unstructured":"Frantz C, Avouac J, Distler O, Amrouche F, Godard D, Kennedy AT et al (2016) Impaired quality of life in systemic sclerosis and patient perception of the disease: A large international survey. Semin Arthritis Rheum 46:115\u2013123. https:\/\/doi.org\/10.1016\/j.semarthrit.2016.02.005","journal-title":"Semin Arthritis Rheum"},{"key":"5613_CR39","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1093\/rheumatology\/keac118","volume":"61","author":"NM van Leeuwen","year":"2022","unstructured":"van Leeuwen NM, Boonstra M, Fretheim H, Brunborg C, Midtvedt O, Garen T et al (2022) Gastrointestinal symptom severity and progression in systemic sclerosis. Rheumatology (Oxford) 61:4024\u20134034. https:\/\/doi.org\/10.1093\/rheumatology\/keac118","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 106","key":"5613_CR40","first-page":"214","volume":"35","author":"R Kamei","year":"2017","unstructured":"Kamei R, Yamaoka T, Ikinaga K, Murota H, Shimizu K, Katayama I (2017) Successful treatment of a refractory dysbiotic intestinal pseudo-obstruction in a patient with systemic sclerosis-polymyositis overlap syndrome by intravenous immunoglobulin administration possibly related to gut flora normalisation. Clin Exp Rheumatol 35(Suppl 106):214\u2013215","journal-title":"Clin Exp Rheumatol"},{"key":"5613_CR41","doi-asserted-by":"publisher","first-page":"170","DOI":"10.3109\/03009742.2013.868510","volume":"43","author":"W Mauhin","year":"2014","unstructured":"Mauhin W, Rivi\u00e8re S, Cabane J, Tiev KP (2014) Improvement in lung fibrosis using intravenous immunoglobulin in systemic sclerosis with myositis. Scand J Rheumatol 43:170\u2013171. https:\/\/doi.org\/10.3109\/03009742.2013.868510","journal-title":"Scand J Rheumatol"},{"key":"5613_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s10067-013-2422-0","volume":"33","author":"M Iudici","year":"2014","unstructured":"Iudici M, Fasano S, Iacono D, Russo B, Cuomo G, Valentini G (2014) Prevalence and factors associated with glucocorticoids (GC) use in systemic sclerosis (SSc): a systematic review and meta-analysis of cohort studies and registries. Clin Rheumatol 33:153\u2013164. https:\/\/doi.org\/10.1007\/s10067-013-2422-0","journal-title":"Clin Rheumatol"},{"key":"5613_CR43","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/rheumatology\/ker271","volume":"51","author":"L Guillevin","year":"2012","unstructured":"Guillevin L, Berezne A, Seror R, Teixeira L, Pourrat J, Mahr A et al (2012) Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology (Oxford) 51:460\u2013467. https:\/\/doi.org\/10.1093\/rheumatology\/ker271","journal-title":"Rheumatology (Oxford)"},{"key":"5613_CR44","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1080\/14397595.2016.1270796","volume":"27","author":"M Iudici","year":"2017","unstructured":"Iudici M (2017) What should clinicians know about the use of glucocorticoids in systemic sclerosis? Mod Rheumatol 27:919\u2013923. https:\/\/doi.org\/10.1080\/14397595.2016.1270796","journal-title":"Mod Rheumatol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05613-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05613-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05613-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T21:25:40Z","timestamp":1727299540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05613-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,15]]},"references-count":44,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["5613"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05613-5","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,15]]},"assertion":[{"value":"17 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LC has not received fees or personal grants from any laboratory. Still, her institute works by contract for laboratories among other institutions, such as Amgen, Fresenius Kabi Espa\u00f1a, Galapagos, Gilead, Pfizer, Lilly, Meda Pharma, MSD, Novartis, Roche, Sanofi Aventis, Upjohn, BMS, Novo Nordisk, and Sandoz. In addition, LC seats, but does not receive personal remuneration, in Safety Monitoring Boards: Lilly and Hospital Cl\u00ednico San Carlos.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}